Category: News

International rare disease day! Over 300 million people around the world are living with a rare disease! Then imagine how many of us are affected by rare diseases – whether as patients ourselves, caregivers, family members, or friends. While individually these conditions may affect only a small number of people, collectively they represent a significant portion […]

More great news before Christmas! We are happy to announce the appointment of Dr. Maria Lahtinen as the Chief Development Officer. Dr. Lahtinen has diligently served as the company’s Quality Director for the past year. The company’s CEO, Dr. Maksimow, expressed his excitement, stating, “I am thrilled to have Maria as our CDO, especially as we progress SAR003, […]

The board of Sartar Therapeutics Oy is delighted to announce Dr. Mikael Maksimow as the new CEO of the company. Dr. Maksimow officially assumed his role on December 7th, following more than two years of dedicated service as Sartar’s Chief Operating Officer. “We are excited to have Mikael, a seasoned, dynamic, and innovative CEO, spearheading […]

Sartar Therapeutics is present in Nordic Life Science Days! Come and meet us or book a meeting during the event! We are looking for Series A funding or co-development partners for our SAR003 treatment for GISt and other soft tissue sarcoma subtypes.

CTOS meeting in Dublin was well organised with highly interesting program. It was great to meet old friends and make new ones. We had very good talks with key opinion leaders, investors and patient advocacy groups. 

We are delighted to announce that Sartar Therapeutics received Orphan Drug Designation for GIST from the U.S. Food & Drug administration (FDA). This is a great addition to our Orphan Drug Designation in EU granted by the European Medicines Agency (EMA) earlier this year. See Orphan Drug Designation in FDA’s database.

Sartar Therapeutics is presenting at the Showcase Biotech stage on 3rd May at 15:30. Come and see us or book a meeting during the event! LSX Congress 3-4 May, Business Design Center, London, UK.

We are pleased to announce that Sartar Therapeutics has been granted orphan drug designation in EU by the European Commission. See more on Community Register of orphan medicinal products.

Maria Lahtinen has been appointed to the role of Quality Director since 1st Jan 2023 to support the company growth and transfer from preclinical to clinical stage. Maria has a long pharma experience in various drug development activities from laboratory to clinics in companies of various sizes. At Sartar her main responsiblity is to develop […]

Sartar Therapeutics is strengthening its board with two new board members, Jyrki Mattila and Jami Mandelin, who will bring decades of experience in the biotech industry and healthcare business to the company. Jyrki Mattila’s career in the pharma & biotech space spans for over forty years in Europe and in the U.S. Prior to moving to the […]